Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 8/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 4/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23215939 | 1.00 | TACR3 (0.36) | TACR3DPP4DPP7RORCDPP8 | |
| SCHEMBL23215710 | 0.93 | TACR3 (0.37) | TACR3DPP4RORCDPP8MGLL | |
| SCHEMBL29745372 | 0.93 | TACR3 (0.37) | TACR3DPP4RORCDPP8MGLL | |
| SCHEMBL23215713 | 0.93 | TACR3 (0.37) | TACR3DPP4RORCDPP8MGLL | |
| SCHEMBL23215708 | 0.93 | TACR3 (0.37) | TACR3DPP4RORCDPP8MGLL | |
| SCHEMBL23230791 | 0.93 | TACR3 (0.37) | TACR3DPP4RORCDPP8MGLL | |
| Trifluoroacetic Acid SCHEMBL23216073 | 0.92 | DPP4 (0.35) | DPP4DPP7DPP8DPP9CCR4 | |
| Trifluoroacetic Acid SCHEMBL23216076 | 0.92 | DPP4 (0.35) | DPP4DPP7DPP8DPP9CCR4 | |
| Trifluoroacetic Acid SCHEMBL23215328 | 0.90 | DPP4 (0.36) | DPP4DPP7DPP8DPP9CCR4 | |
| Trifluoroacetic Acid SCHEMBL23215332 | 0.90 | DPP4 (0.36) | DPP4DPP7DPP8DPP9CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | TACR3 184/4885DPP4 2667/4885DPP7 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.